Back to top
more

Quest Diagnostics (DGX)

(Delayed Data from NYSE)

$153.56 USD

153.56
472,339

+0.72 (0.47%)

Updated Aug 23, 2024 04:00 PM ET

After-Market: $153.57 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 251)

Industry: Medical - Outpatient and Home Healthcare

Better trading starts here.

Zacks News

Why Is Quest Diagnostics (DGX) Up 3% Since Last Earnings Report?

Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

DGX vs. CHE: Which Stock Is the Better Value Option?

DGX vs. CHE: Which Stock Is the Better Value Option?

Quest Diagnostics (DGX) Jumps: Stock Rises 9.3%

Quest Diagnostics (DGX) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

Quest Diagnostics (DGX) Q1 Earnings Top Mark, Margins Down

Quest Diagnostics (DGX) currently concentrates on its core diagnostic information services business and tries to maintain discipline in capital deployment.

Sweta Jaiswal headshot

Bright Near-Term Outlook for Medical Info Systems Industry

The wave of digital transition is helping players in the Zacks Medical Info Systems industry to open up bountiful opportunities for investors.

Can Five Elements Drive Quest Diagnostics (DGX) Q1 Earnings?

Quest Diagnostics (DGX) seems in sync with its strategy to expedite growth and operational excellence.

Quest Diagnostics (DGX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Quest Diagnostics (DGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Quest Diagnostics Grows on New Pacts Amid Reimbursement Issue

Quest Diagnostics' (DGX) partnership with UnitedHealthcare to operate as a preferred national laboratory seems strategic for the latter's customers.

Quest Diagnostics (DGX) Up 3.5% Since Last Earnings Report: Can It Continue?

Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Should Value Investors Pick Quest Diagnostics (DGX) Stock?

Let's see if Quest Diagnostics (DGX) stock is a good choice for value-oriented investors right now from multiple angles.

Quest Diagnostics Ties Up With RMC to Deliver Lab Services

Quest Diagnostic's (DGX) partnership with RMC is set to better the quality of patient care.

Quest Diagnostics Grows on Innovation Amid Reimbursement Woe

Quest Diagnostics' (DGX) progress in prescription drug monitoring, QuantiFERON and non-invasive prenatal screening are part of its recent major developments.

Quest Diagnostics (DGX) Q4 Earnings in Line, Margins Down

In recent times, Quest Diagnostics (DGX) is facing several reimbursement issues which have hurt revenues.

Quest Diagnostics (DGX) Q4 Earnings Meet Estimates

Quest Diagnostics (DGX) delivered earnings and revenue surprises of 0.00% and -2.42%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

Can M&A Activity Drive Quest Diagnostics (DGX) Q4 Earnings?

Quest Diagnostics' (DGX) increasing partnerships with other health care leaders and strategic acquisitions are promising abundant opportunities for the company's top and bottom-line improvement.

Earnings Preview: Quest Diagnostics (DGX) Q4 Earnings Expected to Decline

Quest Diagnostics (DGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Quest Diagnostics' Core Diagnostics Strong Amid Several Woes

Quest Diagnostics' (DGX) steady efforts to intensify focus on core diagnostic information services business and an intelligent capital management give investors ample reasons to cheer for.

Quest Diagnostics (DGX) Divests India Business to Strand

Quest Diagnostics (DGX) sees lucrative prospects in the U.S. diagnostic testing market.

Amazon Eyeing Diagnostic Space to Gather Steam in Healthcare

Amazon's (AMZN) growing healthcare initiatives are likely to aid its growth in the healthcare supply chain management market.

Myriad Genetics Announces Encouraging EndoPredict Test Data

Myriad Genetics (MYGN) forges ahead with initiatives to boost the adoption of the EndoPredict tests.

Quest Diagnostics Rides on Product Launches, Strategic Deals

Quest Diagnostics' (DGX) consistent efforts to refocus on core diagnostic information services business and disciplined capital deployment buoy optimism on the stock.

Near-Term Outlook for Medical Information Systems Industry

The wave of digital transition is helping companies in the Zacks Medical Info Systems industry to create opportunities for investors.

Company News For Nov 30, 2018

Companies In The News Are: DLTR,ANF,DGX,NLSN

Quest Diagnostics to Buy Laboratory Services Unit in Midwest

Quest Diagnostics (DGX) continues to expand inorganically. The latest buyout is expected to expand the company's portfolio in the Midwest.

Bright Outlook for Outpatient and Home Healthcare Industry

Here we discuss how outpatient and home healthcare have been creating opportunities for investors keen on parking their money in this space.